SELECTIVE DELIVERY OF ANTICANCER DRUG ON LIPOSOMES

Isaac Izcoatl Mota Díaz\textsuperscript{1}, Janna Douda\textsuperscript{1} and Patricia García-Lopéz\textsuperscript{2}

\textsuperscript{1}UPIITA – Instituto Politécnico Nacional, Othón Mendizábal S/N, La Escalera, 07320, México D. F., México. \textsuperscript{2} Instituto Nacional de Cancerología, Subdirección de Investigación Básica, Tlalpan, C.P. 14080, México D.F., México

Paclitaxel is potent chemotherapeutic drug used in the treatment of cancer \cite{1}. In the present study, hybrid liposome-Paclitaxel nanoparticles were developed to investigate the therapeutic potential of liposome encapsulated drug with selective delivery. Selective delivery was produced by peptide targeting of liposomes based on overexpressing of bombesin receptors by breast cancer cells \cite{2,3}. The PEGilated liposomes were prepared via a thin-film hydration technique and characterized by Transmission Electron Microscopy, and Dynamic Light Scattering. In vitro experiments of present hybrid system shows a potential clinical use of the new liposomes for Paclitaxel delivery in breast cancer therapy.

\textbf{Keywords}: Liposome, Paclitaxel, Bombesin

\textbf{References}:


Presenting author’s email: jannaduda@hotmail.com